Is HCA Healthcare (HCA) overvalued or fairly valued?

MarketChacha shows HCA Healthcare's valuation in context — a trailing P/E of about 15.1, a forward P/E of about 12.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does HCA Healthcare's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.83×) from reported figures — education, not a rating.

What is HCA Healthcare's revenue?

HCA Healthcare reported revenue of $75.6B for FY2025, with net profit of $6.8B, per official filings.

What is the share price of HCA Healthcare (HCA)?

HCA Healthcare last traded at $414.03 (+0.2% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

HCA Healthcare

HCA · NYSE · Healthcare · United States

Snapshot

TickerHCA

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees230,000

HeadquartersNashville, United States

Websitewww.hcahealthcare.com

Filings tracked19

About HCA Healthcare

HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Who owns it

Insiders16.6%
Institutions80.4%
Public & other3.0%

1,864 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.6.01%
Vanguard Capital Management LLC4.70%
Sanders Capital, LLC4.14%
State Street Corporation3.45%
FMR, LLC2.03%
Wellington Management Group, LLP1.80%
Geode Capital Management, LLC1.71%
First Eagle Investment Management, LLC1.52%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.83×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend8.1% → 9.0%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 8% · PAT 14%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $19.9B · EPS 7.98

Est. earnings growth -0.4%

Next fiscal year

Rev $81.6B · EPS 32.16

Est. earnings growth +8.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$75.6B

Net margin

9.0%

Revenue CAGR (2y)

+7.9%

Profit CAGR (2y)

+13.8%

EPS (FY2025)

28.33

Net profit (FY2025)

$6.8B

Ask MarketChacha about HCA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2025	$75.6B	$6.8B	28.33	9.0%
FY2024	$70.6B	$5.8B	22.00	8.2%
FY2023	$65.0B	$5.2B	18.97	8.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$19.1B	$1.6B	7.15	8.5%
2025Q3	$19.2B	$1.6B	6.96	8.6%
2025Q2	$18.6B	$1.7B	6.83	8.9%
2025Q1	$18.3B	$1.6B	6.45	8.8%
2024Q3	$17.5B	$1.3B	4.88	7.3%
2024Q2	$17.5B	$1.5B	5.53	8.4%
2024Q1	$17.3B	$1.6B	5.93	9.2%
2023Q3	$16.2B	$1.1B	3.91	6.7%
2023Q2	$15.9B	$1.2B	4.29	7.5%
2023Q1	$15.6B	$1.4B	4.85	8.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material financial obligation, Other events
SEC7/29/2026material
10-Q filing
SEC7/28/2026
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC7/24/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/14/2026material
8-K — Executive/director change
SEC6/18/2026material
8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/29/2026
8-K — Shareholder vote results
SEC4/28/2026material
8-K — Other events, Exhibits
SEC4/27/2026material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC4/24/2026material
8-K — Executive/director change, Exhibits
SEC2/25/2026material
10-K filing
SEC2/10/2026
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC1/27/2026material

2025

8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC10/31/2025material
10-Q filing
SEC10/30/2025
8-K — Other events, Exhibits
SEC10/27/2025material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC10/24/2025material
10-Q filing
SEC8/4/2025
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC7/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.